Investment Trusts

BioPharma Credit PLC

BPCR:LSE

BioPharma Credit PLC

Actions
  • Price (USD)0.884
  • Today's Change0.004 / 0.45%
  • Shares traded954.84k
  • 1 Year change+5.24%
  • Beta0.1186
Data delayed at least 20 minutes, as of Jun 30 2025 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Total returns on $1000

1Y
Fund/benchmarkChange
PriceBioPharma Credit PLC (Ordinary Share)+20.26%
NAVBioPharma Credit PLC (Ordinary Share)+15.34%
Morningstar's BenchmarkNo benchmark--

Key statistics

BioPharma Credit PLC (BPCR:LSE) set a new 52-week low during today's trading session when it reached 0.80. Over this period, the share price is down 5.24%.
52-week range
Today
0.80Apr 09 20250.9798Jun 30 2025
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Shares outstanding1.13bn
Market cap993.81m USD
Total assets1.13bn USD
Total expense ratio1.17%
High0.884
Low0.88
Previous close0.88
Average volume716.81k
YTD Change0.00%
Beta0.1186
Diluted NAV (est)0.998
Diluted NAV (last pub)1.01
Premium/Discount-11.42%
Net Gearing0.00%
Annual div (ADY)0.07
USD
Annual div yield (ADY)7.95%
Div ex-dateJun 26 2025
Div pay-dateJul 31 2025
Data delayed at least 20 minutes, as of Jun 30 2025 16:35 BST.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.